Celltrion invalidates Roche’s Rituxan® patent

Sep 20, 2022

Korea Biomedical Review reported that Celltrion has successfully invalidated a Taiwanese Roche rituximab patent relating to the treatment of rheumatoid arthritis.  Celltrion reported that it will now expand its label in Taiwan to include all indications of Rituxan®.

Print Page Mail Article